Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

The chief medical officer of Amazon.com's pharmacy unit is hopeful that U.S. health secretary nominee Robert F. Kennedy Jr.

The murder of Brian Thompson, the CEO of UnitedHealth's insurance arm, ignited an outpouring of anger from Americans ...

Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with ongoing Seagen ...

Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...

Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...